ATRC News and Press, AtriCure Inc. From 08/13/19

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial a...

Investors appear to lack enthusiasm for AtriCure's ( ATRC -8.1% ) planned takeover of SentreHEART, the developer of a suture delivery device called LARIAT for left atrial appendage closure. More news on: AtriCure, Inc., Healthcare stocks news, Merger & acquisition news, Stocks on t...

AtriCure (NASDAQ: ATRC ) has agreed to acquire privately held SentreHEART , a developer of percutaneous left atrial appendage management solutions. More news on: AtriCure, Inc., Healthcare stocks news, Merger & acquisition news, Read more ...

Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12 th at 8:30am ET AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atri...

The following slide deck was published by AtriCure, Inc. in conjunction with this Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

AtriCure, Inc. (ATRC) Q2 2019 Results Conference Call July 30, 2019 04:30 PM ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President and Chief Executive Officer Andy Wade - Senior Vice President and Chief Financial Officer Conference Call Participants C...

AtriCure (NASDAQ: ATRC ): Q2 Non-GAAP EPS of -$0.17 in-line; GAAP EPS of -$0.11 beats by $0.06 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Worldwide revenue of $58.9 million – an increase of 13.7% year over year U.S. revenue of $47.2 million – an increase of 15.5% year over year International revenue of $11.7 million – an increase of 7.0% year over year AtriCure, Inc. ( Nasdaq: ATRC ),...